Anteris Technologies Global Corp. (AVR)
NASDAQ:AVR
Top Page
Anteris Technologies Global Corp.
(NASDAQ:AVR)
Select Model
Select Model
Rating:56Neutral
Price Target:
$5.50
▲(1.10% Upside)
Action:ReiteratedDate:02/27/26
The score is held back primarily by weak financial performance (shrinking revenue, very large losses, negative equity, and heavy cash burn). Offsetting factors include improving technical momentum (price above key moving averages with positive MACD) and a major $320M financing tied to the PARADIGM trial and Medtronic alignment, which supports execution and near-term funding.
Positive Factors
Strategic Medtronic financing
The $320M financing, including a $90M strategic equity investment from a Medtronic subsidiary, materially extends runway to execute the PARADIGM pivotal trial and early commercialization steps. This durable capital reduces near-term funding risk and aligns a major industry partner with execution and market access over coming quarters.
Negative Factors
Declining revenue trend
Revenue has trended meaningfully lower over several years, shrinking the top line to levels that cannot support current operating cost structure. Persistent revenue decline undermines the firm's ability to scale, leverage fixed costs, and reach self‑sustaining operations without sustained commercial uptake or new revenue streams.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic Medtronic financing
The $320M financing, including a $90M strategic equity investment from a Medtronic subsidiary, materially extends runway to execute the PARADIGM pivotal trial and early commercialization steps. This durable capital reduces near-term funding risk and aligns a major industry partner with execution and market access over coming quarters.
Read all positive factors
Anteris Technologies Global Corp. (AVR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$528.94M
Dividend YieldN/A
Average Volume (3M)151.40K
Price to Earnings (P/E)―
Beta (1Y)2.00
Revenue Growth-21.10%
EPS Growth-18.32%
CountryUS
Employees136
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.74
Shares Outstanding97,232,056
10 Day Avg. Volume215,658
30 Day Avg. Volume151,395
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)-1.27K
Price to Sales (P/S)61.50
P/FCF Ratio-1.48
Enterprise Value/Market Cap0.36
Enterprise Value/Revenue99.23
Enterprise Value/Gross Profit141.25
Enterprise Value/Ebitda-2.06
Forecast
1Y Price Target
$15.75Price Target Upside189.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.32
Revenue Forecast (FY)$8.58M
Anteris Technologies Global Corp. Business Overview & Revenue Model
Company Description
Anteris Technologies Global Corp., a structural heart company, discovers, develops, and commercializes medical devices to enhance the quality of life for patients with aortic stenosis. Its lead product candidate is the DurAVR transcatheter heart v...
How the Company Makes Money
null...
Anteris Technologies Global Corp. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
10
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.91M | 2.70M | 2.73M | 3.20M | 5.83M |
| Gross Profit | 1.34M | 1.27M | 876.80K | 298.38K | 1.91M |
| EBITDA | -92.49M | -76.86M | -45.54M | -29.14M | -15.50M |
| Net Income | -94.22M | -76.29M | -46.02M | -30.56M | -17.17M |
Balance Sheet | |||||
| Total Assets | 23.00M | 80.70M | 30.53M | 15.99M | 21.43M |
| Cash, Cash Equivalents and Short-Term Investments | 12.58M | 70.46M | 21.03M | 9.29M | 15.46M |
| Total Debt | 2.28M | 1.40M | 1.60M | 952.79K | 4.14M |
| Total Liabilities | 23.25M | 18.02M | 11.63M | 6.95M | 10.91M |
| Stockholders Equity | -93.00K | 62.76M | 19.30M | 9.03M | 10.52M |
Cash Flow | |||||
| Free Cash Flow | -79.76M | -63.51M | -37.03M | -31.08M | -15.02M |
| Operating Cash Flow | -77.80M | -61.24M | -34.63M | -29.42M | -14.44M |
| Investing Cash Flow | -596.00K | -2.28M | -2.58M | -992.57K | -886.07K |
| Financing Cash Flow | 20.55M | 112.83M | 49.34M | 23.27M | 27.42M |
Anteris Technologies Global Corp. Technical Analysis
Positive
5.44
Price Trends
5.87
Negative
5.30
Positive
4.73
Positive
Market Momentum
-0.18
Positive
45.85
Neutral
36.60
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AVR, the sentiment is Positive. The current price of 5.44 is below the 20-day moving average (MA) of 5.67, below the 50-day MA of 5.87, and above the 200-day MA of 4.73, indicating a neutral trend. The MACD of -0.18 indicates Positive momentum. The RSI at 45.85 is Neutral, neither overbought nor oversold. The STOCH value of 36.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AVR.
Anteris Technologies Global Corp. Risk Analysis
Anteris Technologies Global Corp. disclosed 66 risk factors in its most recent earnings report. Anteris Technologies Global Corp. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
Medtronic beneficially owns a significant equity interest in us and its interests may conflict with our or your interests. Q4, 2025
2.
Artificial intelligence technologies could present business, compliance and reputational risks. Q4, 2025
Anteris Technologies Global Corp. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $203.83M | -12.67 | -7.42% | ― | -31.29% | 65.68% | |
56 Neutral | $528.94M | -1.25 | -2462.70% | ― | -21.10% | -18.32% | |
56 Neutral | $181.64M | -8.03 | -11.56% | ― | 4.68% | 55.37% | |
52 Neutral | $159.37M | -13.16 | -117.54% | ― | -1.32% | 55.62% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $104.11M | -2.75 | -68.83% | ― | 16.63% | 10.43% | |
41 Neutral | $90.43M | -2.63 | -51.63% | ― | 7.90% | 19.92% |
* Healthcare Sector Average
AVR
Anteris Technologies Global Corp.
5.44
2.50
85.03%
ANIK
Anika Therapeutics
15.21
1.61
11.84%
APYX
Apyx Medical
3.81
2.93
332.95%
INGN
Inogen
6.67
-0.41
-5.79%
TMCI
Treace Medical Concepts
1.40
-5.59
-79.97%
RPID
Rapid Micro Biosystems
2.29
0.19
9.05%
Anteris Technologies Global Corp. Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Anteris Technologies Secures $320 Million for PARADIGM Trial
Positive
Jan 22, 2026
On January 22, 2026, Anteris Technologies Global Corp. and Medtronic announced that Anteris had completed a $90 million strategic equity investment from Medtronic, immediately following an underwritten offering of common stock, for total gross pro...
Business Operations and StrategyPrivate Placements and Financing
Anteris Technologies Announces Major Equity Offering and Medtronic Deal
Positive
Jan 22, 2026
On January 20, 2026, Anteris Technologies Global Corp. agreed to an underwritten public offering of 34,782,609 common shares at $5.75 per share and granted underwriters a 30‑day option for an additional 5,217,391 shares, which was fully exer...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.